Point-of-care group EKF Diagnostics Holdings posted a large rise in annual profit after it booked a gain on the spin-off of its biomarker unit Renalytix AI. Pre-tax profit for the year through December rose to £12.2m, up from £4.3m on-year. Revenue rose 2% to £42.5m, while gross profit fell slightly to £22.7m. 'This has been a very successful year, which has allowed us to provide significant rewards for shareholders,' chief executive Christopher Mills said. 'We are confident that we will continue to make progress in 2019.' 'Trading in the first quarter to date has been satisfactory, in line with management expectation.' At 2:35pm: (LON:EKF) EKF Diagnostics Holdings PLC share price was -1.15p at 30.55p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.